Cost-utility analysis of breast reduction surgery for women with symptomatic breast hypertrophy.

The Medical journal of Australia 2022 Vol.216(3) p. 147-152

Crittenden TA, Ratcliffe J, Watson DI, Mpundu-Kaambwa C, Dean NR

관련 도메인

Abstract

[OBJECTIVE] To assess the cost-effectiveness of breast reduction surgery for women with symptomatic breast hypertrophy in Australia.

[DESIGN] Cost-utility analysis of data from a prospective cohort study.

[SETTING, PARTICIPANTS] Adult women with symptomatic breast hypertrophy assessed for bilateral breast reduction at the Flinders Medical Centre, a public tertiary hospital in Adelaide, April 2007 - February 2018. The control group included women with breast hypertrophy who had not undergone surgery.

[MAIN OUTCOME MEASURES] Health care costs (for the surgical admission and other related hospital costs within 12 months of surgery) and SF-6D utility scores (measure of health-related quality of life) were used to calculate incremental costs per quality-adjusted life-year (QALY) gained over 12 months, extrapolated to a 10-year time horizon.

[RESULTS] Of 251 women who underwent breast reduction, 209 completed the baseline and at least one post-operation assessment (83%; intervention group); 124 of 350 invited women waiting for breast reduction surgery completed the baseline and 12-month assessments (35%; control group). In the intervention group, the mean SF-6D utility score increased from 0.313 (SD, 0.263) at baseline to 0.626 (SD, 0.277) at 12 months; in the control group, it declined from 0.296 (SD, 0.267) to 0.270 (SD, 0.257). The mean QALY gain was consequently greater for the intervention group (adjusted difference, 1.519; 95% CI, 1.362-1.675). The mean hospital cost per patient was $11 857 (SD, $4322), and the incremental cost-effectiveness ratio (ICER) for the intervention was $7808 per QALY gained. The probability of breast reduction surgery being cost-effective was 100% at a willingness-to-pay threshold of $50 000 per QALY and 88% at $28 033 per QALY.

[CONCLUSIONS] Breast reduction surgery for women with symptomatic breast hypertrophy is cost-effective and should be available to women through the Australian public healthcare system.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 12
시술 breast reduction 유방성형술 dict 7
약물 [OBJECTIVE] scispacy 1
약물 [DESIGN] Cost-utility scispacy 1
약물 [MAIN OUTCOME scispacy 1
약물 [CONCLUSIONS] Breast scispacy 1
질환 breast hypertrophy C0020565
Hypertrophy of Breast
scispacy 1
기타 women scispacy 1
기타 patient scispacy 1

MeSH Terms

Adult; Australia; Breast; Breast Diseases; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Hypertrophy; Mammaplasty; Middle Aged; Prospective Studies; Quality-Adjusted Life Years

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문